Castle Biosciences, a company improving health through innovative tests that guide patient care, agreed to acquire AltheaDx, a molecular diagnostics company, for $140m. “As a company, we focus on transforming disease management through the personalized information our innovative tests provide. Similar to our acquisition of Cernostics in December 2021, the pending acquisition of AltheaDx enables us to offer a testing solution that we believe has the potential to accelerate our impact on patient care in an area of high unmet clinical need, significantly expand our in-market expected estimated US TAM to approximately $8bn and offer incremental value to patients and clinicians over standard of care. Further, this acquisition would enable us to potentially develop a mental health franchise, starting with a test that currently receives Medicare reimbursement for depression," Derek Maetzold, Castle CEO.